LWM
SPRO icon

Liberty Wealth Management’s Spero Therapeutics SPRO Stock Holding History

Liberty Wealth Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,000
Closed -$37K – 970
2021
Q3 		$37K Hold
2,000
– – 0.01% 483
2021
Q2 		$28K Hold
2,000
– – 0.01% 438
2021
Q1 		$38K Hold
2,000
– – 0.02% 336
2020
Q4 		$38K Hold
2,000
– – 0.02% 333
2020
Q3 		$22K Buy
+2,000
New +$23.7K 0.01% 385

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Liberty Wealth Management's SPRO Position: Q4 2021 in Review

Liberty Wealth Management sold out of Spero Therapeutics (SPRO) in Q4 2021, closing a stake of 2,000 shares — an estimated $37K sold.

Liberty Wealth Management first reported a position in SPRO in Q3 2020 and held it in 5 quarters. The position peaked at $38K in Q1 2021. 84 funds tracked by Wall St. Rank hold SPRO as of Q4 2021.

  • Liberty Wealth Management reported no remaining Spero Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Liberty Wealth Management sold 2,000 Spero Therapeutics shares in Q4 2021, an estimated $37K.
  • Liberty Wealth Management first reported a position in Spero Therapeutics in Q3 2020 and held it in 5 quarters.
  • Liberty Wealth Management's Spero Therapeutics position peaked at $38K in Q1 2021.
  • 84 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2021.

Based on Liberty Wealth Management's 13F filing for Q4 2021, filed 15 Feb 2022.